Clinical Trials Directory

Trials / Unknown

UnknownNCT03457298

Lateral Ridge Augmentation Using a Volume Maintaining Collagen Scaffold Versus Allograft With Collagen Membrane.

Lateral Ridge Augmentation Using a Volume Maintaining Collagen Scaffold (Ossix Volumax) Versus Freeze-dried Bone Allograft (FDBA) With Collagen Membrane

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Rambam Health Care Campus · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Accepted

Summary

The aim of the current study is to compare lateral bone augmentation using the current gold standard (FDBA plus resorbable collagen membrane) versus Ossix Volumax as a stand-alone material.

Detailed description

One of the major problems in implant therapy is the need to regenerate bone after its resorption because of periodontal disease, traumatic extraction or surgical removal associated with treatment of invasive lesions. Ossix Volumax is a novel volume maintaining collagen scaffold designed for bone augmentation in the atrophic ridge. It is 1-2 mm in thickness and undergoes mineralization progressing into ossification. Thirty subjects requiring lateral bone augmentation of the maxilla or the mandible will be recruited study: Of these, twenty will be recruited and treated at the School of Dental Medicine, Harvard University, Boston, USA and ten (10) at the School of Graduate Dentistry, Rambam health care campus, Haifa, Israel. Hypothesis: The use of Ossix Volumax as a stand-alone augmentation material will results similar increase in the ridge width and volume compared to FDBA and barrier membrane when coupled together.

Conditions

Interventions

TypeNameDescription
DEVICEOssix VolumaxOssix Volumax is intended to be used for Lateral ridge augmentation
DEVICEFDBA with collagen membranefreeze-dried bone allograft (FDBA) with collagen membrane

Timeline

Start date
2018-11-07
Primary completion
2020-04-01
Completion
2020-07-01
First posted
2018-03-07
Last updated
2019-05-20

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT03457298. Inclusion in this directory is not an endorsement.